21 completed, 6 recruiting, 3 not yet recruiting, 2 enrolling by invitation. 16 Phase 3, 5 Phase 1, 4 Phase 4, 2 Phase 2, 1 Not applicable.
Follow eptinezumab: new trials by email Literature Review of eptinezumab trials Research Report on eptinezumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) Eptinezumab, Placebo - Post Traumatic Headache | Phase 3 | Not yet recruiting | Sunnybrook Health Sciences Centre | 80 | 2026-09-30 | 2026-08-13 |
| Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Galcanezumab, Erenumab 70 mg, Eptinezumab - Migraine Associated Vertigo, Tinnitus | Phase 4 | Not yet recruiting | Stanford University | 120 | 2026-07-01 | 2026-06-17 |
| Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension Eptinezumab, Placebo - Idiopathic Intracranial Hypertension (IIH) | Phase 3 | Not yet recruiting | Rigmor Højland Jensen | 96 | 2026-06-22 | 2026-06-12 |
| Facilitators and Barriers to Eptinezumab Administration in Thailand Eptinezumab, Sham (No Treatment) - Migraine, Treatment | Completed | Chulalongkorn University | 30 | 2025-08-25 | 2026-04-08 | |
| Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Eptinezumab, Standard of Care - Migraine, Chronic Migraine | Phase 3 | Enrolling by invitation | Dr George Medvedev | 102 | 2025-05-05 | 2026-09-30 |
| A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy Eptinezumab, Placebo - Diabetic Polyneuropathy | Phase 2 | Withdrawn | Mayo Clinic | 2025-01-01 | 2025-03-06 | |
| A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications Eptinezumab - Migraine | Phase 4 | Completed | H. Lundbeck A/S | 164 | 2024-12-18 | 2026-09-09 |
| The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study) Eptinezumab 100 or 300 mg ev - Migraine | Recruiting | University of Florence | 50 | 2024-10-30 | 2026-01-21 | |
| Migraine Medication Effects on Urinary Symptoms Ubrogepant, Rimegepant, Atogepant - Overactive Bladder, Bladder Pain Syndrome | Enrolling by invitation | The Cleveland Clinic | 200 | 2024-04-05 | 2026-10-19 | |
| Effectiveness and Tolerability of Eptinezumab Eptinezumab 100 or 300 mg ev - Migraine, Migraine With Aura | Completed | University of Florence | 130 | 2024-03-26 | 2026-06-11 | |
| A Study of Eptinezumab in Pediatric Participants With Episodic Migraine Eptinezumab, Placebo - Episodic Migraine | Phase 3 | Recruiting | H. Lundbeck A/S | 315 | 2023-06-08 | 2026-10-14 |
| Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients. Eptinezumab, PACAP-38 - Migraine | Not applicable | Completed | Danish Headache Center | 38 | 2023-03-01 | 2023-12-04 |
| EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine. Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution - Migraine Disorders | Recruiting | IRCCS San Raffaele Roma | 500 | 2023-01-01 | 2025-05-01 | |
| China HeadAche DIsorders RegiStry Medicine Overuse Headache/New Daily Persistent Headache, Episodic Migraine and Chronic Migraine, Patients with other types of primary headache - Headache Disorders, Primary, Migraine | Recruiting | Beijing Tiantan Hospital | 10000 | 2022-08-29 | 2026-07-10 | |
| A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Eptinezumab, Placebo - Migraine, Medication Overuse Headache | Phase 4 | Completed | H. Lundbeck A/S | 608 | 2022-07-01 | 2026-01-29 |
| Real World Effectiveness of Eptinezumab in Participants With Migraine Eptinezumab, Erenumab, Onabotulinumtoxin-A - Migraine | Phase 4 | Terminated | H. Lundbeck A/S | 32 | 2022-03-04 | 2024-05-29 |
| A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine Eptinezumab - Migraine | Phase 3 | Recruiting | H. Lundbeck A/S | 600 | 2021-12-01 | 2026-10-14 |
| Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Eptinezumab - Migraine | Phase 3 | Completed | H. Lundbeck A/S | 160 | 2021-09-21 | 2026-01-14 |
| A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) Eptinezumab - Chronic Cluster Headache | Phase 3 | Completed | H. Lundbeck A/S | 131 | 2021-09-17 | 2024-08-06 |
| A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine Eptinezumab, Placebo - Chronic Migraine in Children | Phase 3 | Recruiting | H. Lundbeck A/S | 285 | 2021-06-30 | 2026-10-16 |
Showing 20 of 34. Sign in to see all of them.
Migraine Disorders (26) · Headache Disorders, Secondary (4) · Headache (3) · Cluster Headache (2) · Pain (2) · Cystitis, Interstitial (1) · Diabetic Neuropathies (1) · Emergencies (1) · Headache Disorders, Primary (1) · Migraine with Aura (1) · Migraine without Aura (1) · Post-Traumatic Headache (1) · Pseudotumor Cerebri (1) · Tension-Type Headache (1) · Tinnitus (1)
H. Lundbeck A/S (16) · Alder Biopharmaceuticals, Inc. (6) · University of Florence (2) · Beijing Tiantan Hospital (1) · Chulalongkorn University (1) · Danish Headache Center (1) · Dr George Medvedev (1) · IRCCS San Raffaele Roma (1) · Mayo Clinic (1) · Rigmor Højland Jensen (1) · Stanford University (1) · Sunnybrook Health Sciences Centre (1) · The Cleveland Clinic (1)
United States (18) · Italy (11) · Spain (10) · Georgia (9) · Denmark (7) · United Kingdom (7) · Canada (5) · Germany (5) · Poland (5) · China (4) · France (4) · Japan (4) · Portugal (4) · Argentina (3) · Australia (3)
Akarin Hiransuthikul, MD, MSc (1) · Howard B Goldman, MD (1) · Howard Meng, MD (1) · Jeff Smith, MD (1) · Jeff TL Smith, MD (1) · Kristen K. Steenerson (1) · Matthew Fitzgerald (1) · Narayan Kissoon, MD (1) · Peter Hodsman, MD (1) · Piero Barbanti, MD, PhD (1) · Prakit Anukoolwittaya, MD (1) · Rigmor H Jensen, Ass.Professor, Dr.Med. (1) · Sekh Thanprasertsuk, MD (1) · Thanakit Pongpitakmetha, MD, MSc (1)
PMID 33781209, PMID 34823467, PMID 32075406, PMID 35130836, PMID 35131090, PMID 35302389, PMID 35436857, PMID 36284281, PMID 25297013, PMID 31234642, PMID 32209650, PMID 33023473, PMID 33250209, PMID 33740902, PMID 34128999, PMID 35130832, PMID 35189811, PMID 35332807, PMID 35659622, PMID 35716692, PMID 35804294, PMID 35902796, PMID 36068494, PMID 36460983, PMID 36583633, PMID 37098469, PMID 37125484, PMID 37256558, PMID 37378754, PMID 37955564, PMID 37985968, PMID 38102535, PMID 38236314, PMID 38516817, PMID 38549121, PMID 39666143, PMID 39692817, PMID 40229719, PMID 40252664, PMID 40388178, PMID 40444655, PMID 41091746, PMID 41091912, PMID 41223010, PMID 41275111, PMID 41395928, PMID 41603449, PMID 41670910, PMID 41684106, PMID 41834318
2025 (1)